FDA Grants Rolling Review for Palvella’s QTORIN™ Rapamycin NDA — Palvella Therapeutics, Inc.

Event summary

FDA granted rolling review for Palvella's New Drug Application (NDA) for QTORIN™ rapamycin to treat microcystic lymphatic malformations.
Palvella aims to complete NDA submission in the second half of 2026.
QTORIN™ rapamycin is designed to be the first FDA-approved therapy for an estimated 30,000+ U.S. patients with this rare disease.
The drug has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA.

The big picture

Palvella’s QTORIN™ rapamycin represents a potential breakthrough in treating microcystic lymphatic malformations, a rare disease with no current FDA-approved therapies. The rolling review designation underscores the urgency and unmet medical need in this space, positioning Palvella to potentially establish a new standard of care. Success here could validate the company’s platform technology for other rare skin diseases and vascular malformations.

What we're watching

Regulatory Efficiency: How the rolling review process will accelerate FDA evaluation of QTORIN™ rapamycin.
Market Potential: Whether Palvella can capture significant market share in the rare disease space with this first-of-its-kind therapy.
Execution Risk: The pace at which Palvella can complete and submit the full NDA while maintaining regulatory compliance.